• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group

June 3, 2024 | Clinical Journal of the American Society of Nephrology
Carla Nester, et al.

Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group

Carla Nester, Dima A Decker, Matthias Meier, Shakil Aslam, Andrew S. Bomback, Fernando Caravaca-Fontán, Terence H. Cook, David L. Feldman, Veronique Fremeaux-Bacchi, Daniel P. Gale, Ann Gooch, Sally Johnson, Christoph Licht, Mohit Mathur, Matthew C. Pickering, Manuel Praga, Giuseppe Remuzzi, Viknesh Selvarajah, Richard J. Smith, Hossein Tabriziani, Nicole van de Kar, Yaqin Wang, Edwin Wong, Kirtida Mistry, Mark Lim, Cesia Portillo, Seyi Balogun, Howard Trachtman, Aliza Thompson

>READ

© 2025 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design

We use cookies on our website to see how you interact with it. By accepting, you agree to our use of such cookies. Privacy PolicyOk